Generali Investments Management Co LLC Raises Stake in Gilead Sciences, Inc. $GILD

Generali Investments Management Co LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,496 shares of the biopharmaceutical company’s stock after acquiring an additional 4,941 shares during the period. Generali Investments Management Co LLC’s holdings in Gilead Sciences were worth $2,589,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter worth $26,000. Wealth Preservation Advisors LLC raised its position in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter worth $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider directly owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,000 shares of company stock valued at $10,641,790. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on GILD shares. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Wednesday, May 20th. Morgan Stanley decreased their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Truist Financial lowered their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Barclays dropped their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Finally, Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Price Performance

Shares of GILD stock opened at $133.06 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The firm has a market cap of $165.20 billion, a P/E ratio of -49.84 and a beta of 0.32. The business’s 50 day moving average price is $129.45 and its 200-day moving average price is $136.34.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.5 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.